Patents by Inventor Jozef Maria Hendrik Raats
Jozef Maria Hendrik Raats has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230183327Abstract: The invention provides antibodies or binding fragments thereof directed against citrulline-containing epitopes. The antibodies or binding fragments thereof of the invention can be used in therapy, for example in the treatment or prevention of Neutrophil Extracellular Trap (NET)-associated pathologies.Type: ApplicationFiled: May 27, 2022Publication date: June 15, 2023Applicant: CITRYLL B.V.Inventors: Jozef Maria Hendrik RAATS, Renato Gerardus Silvano CHIRIVI, Johannes Wilhelmus Gerardus VAN ROSMALEN
-
Patent number: 11345750Abstract: The invention provides antibodies or binding fragments thereof directed against citrulline-containing epitopes. The antibodies or binding fragments thereof of the invention can be used in therapy, for example in the treatment or prevention of Neutrophil Extracellular Trap (NET)-associated pathologies.Type: GrantFiled: July 6, 2021Date of Patent: May 31, 2022Assignee: CITRYLL B.V.Inventors: Jozef Maria Hendrik Raats, Renato Gerardus Silvano Chirivi, Johannes Wilhelmus Gerardus Van Rosmalen
-
Publication number: 20220073596Abstract: The invention is in the field of methods and preparations for medical treatments, in particular the treatment of idiopathic pulmonary fibrosis (IPF). The invention provides such methods wherein antibodies or fragments thereof that react with selected citrullinated epitopes are used in the treatment of IPF. Antibodies against citrullinated epitopes situated at the amino terminus of hi stone polypeptides H2A and H4 were found to be particularly useful. The invention therefore relates to an antibody specifically reactive with a citrullinated epitope on the N-terminus of deiminated histone H2A or H4 for use in the prevention or treatment of idiopathic pulmonary fibrosis.Type: ApplicationFiled: July 19, 2021Publication date: March 10, 2022Inventors: Renato Gerardus Silvano Chirivi, Jozef Maria Hendrik Raats
-
Publication number: 20210403543Abstract: The invention provides antibodies or binding fragments thereof directed against citrulline-containing epitopes. The antibodies or binding fragments thereof of the invention can be used in therapy, for example in the treatment or prevention of Neutrophil Extracellular Trap (NET)-associated pathologies.Type: ApplicationFiled: July 6, 2021Publication date: December 30, 2021Applicant: CITRYLL B.V.Inventors: Jozef Maria Hendrik RAATS, Renato Gerardus Silvano CHIRIVI, Johannes Wilhelmus Gerardus VAN ROSMALEN
-
Publication number: 20210395350Abstract: The invention provides antibodies or binding fragments thereof directed against citrulline-containing epitopes. The antibodies or binding fragments thereof of the invention can be used in therapy, for example in the treatment or prevention of Neutrophil Extracellular Trap (NET)-associated pathologies.Type: ApplicationFiled: August 20, 2019Publication date: December 23, 2021Applicant: CITRYLL B.V.Inventors: Jozef Maria Hendrik RAATS, Renato Gerardus Silvano CHIRIVI, Johannes Wilhelmus Gerardus VAN ROSMALEN
-
Patent number: 11066462Abstract: The invention is in the field of methods and preparations for medical treatments, in particular the treatment of idiopathic pulmonary fibrosis (IPF). The invention provides such methods wherein antibodies or fragments thereof that react with selected citrullinated epitopes are used in the treatment of IPF. Antibodies against citrullinated epitopes situated at the amino terminus of histone polypeptides H2A and H4 were found to be particularly useful. The invention therefore relates to an antibody specifically reactive with a citrullinated epitope on the N-terminus of deiminated histone H2A or H4 for use in the prevention or treatment of idiopathic pulmonary fibrosis.Type: GrantFiled: December 11, 2015Date of Patent: July 20, 2021Assignee: Citryll B.V.Inventors: Renato Gerardus Silvano Chirivi, Jozef Maria Hendrik Raats
-
Publication number: 20210087260Abstract: This invention is in the field of treating or preventing inflammation in humans and animals and relates to pharmaceutical compositions and methods for treating or preventing various inflammatory conditions. In particular, the invention relates to compositions and methods for treating or preventing inflammatory conditions such as citrulline-related inflammatory diseases. The invention provides specific binding molecules directed against citrulline-containing epitopes for use in the therapy and prevention of inflammatory conditions.Type: ApplicationFiled: August 4, 2020Publication date: March 25, 2021Inventors: Jozef Maria Hendrik Raats, Renato Gerardus Silvano Chirivi
-
Patent number: 10703822Abstract: This invention is in the field of treating or preventing inflammation in humans and animals and relates to pharmaceutical compositions and methods for treating or preventing various inflammatory conditions. In particular, the invention relates to compositions and methods for treating or preventing inflammatory conditions such as citrulline-related inflammatory diseases. The invention provides specific binding molecules directed against citrulline-containing epitopes for use in the therapy and prevention of inflammatory conditions.Type: GrantFiled: June 22, 2017Date of Patent: July 7, 2020Assignee: MODIQUEST B.V.Inventors: Jozef Maria Hendrik Raats, Renato Gerardus Silvano Chirivi
-
Publication number: 20190119368Abstract: This invention is in the field of treating or preventing inflammation in humans and animals and relates to pharmaceutical compositions and methods for treating or preventing various inflammatory conditions. In particular, the invention relates to compositions and methods for treating or preventing inflammatory conditions such as citrulline-related inflammatory diseases. The invention provides specific binding molecules directed against citrulline-containing epitopes for use in the therapy and prevention of inflammatory conditions.Type: ApplicationFiled: December 20, 2018Publication date: April 25, 2019Inventors: Jozef Maria Hendrik Raats, Renato Gerardus Silvano Chirivi
-
Patent number: 10233236Abstract: This invention is in the field of treating or preventing rheumatoid arthritis in humans and animals. In particular, the invention relates to methods for treating or preventing rheumatoid arthritis through treatment with an antibody which specifically reacts with a citrullinated epitope present on a peptide with an amino acid sequence according to SEQ ID NO:21.Type: GrantFiled: June 18, 2015Date of Patent: March 19, 2019Assignee: Modiquest B.V.Inventors: Jozef Maria Hendrik Raats, Renato Gerardus Silvano Chirivi
-
Publication number: 20180319882Abstract: The present invention relates to plexin D1 for use as a targetable protein in the treatment or diagnosis of disorders that involve expression of plexin D1. Diagnosis is suitably effected by detecting the presence of plexin D1 in the body or a bodily tissue or fluid, whereas treatment is effected by targeting plexin D1 for delivery of therapeutics to the site where treatment is needed. The invention further relates to the use of molecules that bind plexin D1, a nucleic acid encoding plexin D1 or a ligand of plexin D1 for the preparation of a therapeutical composition for the treatment or diagnosis of disorders that involve expression of plexin D1. The disorders comprise disorders in which plexin D1 is expressed on tumor cells, tumor blood vessels or activated macrophages.Type: ApplicationFiled: May 3, 2018Publication date: November 8, 2018Inventors: Wilhelmus Petrus Johannes Leenders, Ilse Roodink, Jozef Maria Hendrik Raats
-
Patent number: 9988449Abstract: The present invention relates to plexin D1 for use as a targetable protein in the treatment or diagnosis of disorders that involve expression of plexin D1. Diagnosis is suitably effected by detecting the presence of plexin D1 in the body or a bodily tissue or fluid, whereas treatment is effected by targeting plexin D1 for delivery of therapeutics to the site where treatment is needed. The invention further relates to the use of molecules that bind plexin D1, a nucleic acid encoding plexin D1 or a ligand of plexin D1 for the preparation of a therapeutical composition for the treatment or diagnosis of disorders that involve expression of plexin D1. The disorders comprise disorders in which plexin D1 is expressed on tumor cells, tumor blood vessels or activated macrophages.Type: GrantFiled: July 14, 2016Date of Patent: June 5, 2018Assignee: Modiquest B.V.Inventors: Wilhelmus Petrus Johannes Leenders, Ilse Roodink, Jozef Maria Hendrik Raats
-
Publication number: 20170334978Abstract: The invention is in the field of methods and preparations for medical treatments, in particular the treatment of idiopathic pulmonary fibrosis (IPF). The invention provides such methods wherein antibodies or fragments thereof that react with selected citrullinated epitopes are used in the treatment of IPF. Antibodies against citrullinated epitopes situated at the amino terminus of histone polypeptides H2A and H4 were found to be particularly useful. The invention therefore relates to an antibody specifically reactive with a citrullinated epitope on the N-terminus of deiminated histone H2A or H4 for use in the prevention or treatment of idiopathic pulmonary fibrosis.Type: ApplicationFiled: December 11, 2015Publication date: November 23, 2017Applicant: Modiquest B.V.Inventors: Renato Gerardus Silvano Chirivi, Jozef Maria Hendrik Raats
-
Publication number: 20170298146Abstract: This invention is in the field of treating or preventing inflammation in humans and animals and relates to pharmaceutical compositions and methods for treating or preventing various inflammatory conditions. In particular, the invention relates to compositions and methods for treating or preventing inflammatory conditions such as citrulline-related inflammatory diseases. The invention provides specific binding molecules directed against citrulline-containing epitopes for use in the therapy and prevention of inflammatory conditions.Type: ApplicationFiled: June 22, 2017Publication date: October 19, 2017Applicant: MODIQUEST B.V.Inventors: Jozef Maria Hendrik Raats, Renato Gerardus Silvano Chirivi
-
Patent number: 9718877Abstract: This invention is in the field of treating or preventing inflammation in humans and animals and relates to pharmaceutical compositions and methods for treating or preventing various inflammatory conditions. In particular, the invention relates to compositions and methods for treating or preventing inflammatory conditions such as citrulline-related inflammatory diseases. The invention provides specific binding molecules directed against citrulline-containing epitopes for use in the therapy and prevention of inflammatory conditions.Type: GrantFiled: June 4, 2009Date of Patent: August 1, 2017Assignee: MODIQUEST B.V.Inventors: Jozef Maria Hendrik Raats, Renato Gerardus Silvano Chirivi
-
Publication number: 20160311900Abstract: The present invention relates to plexin D1 for use as a targetable protein in the treatment or diagnosis of disorders that involve expression of plexin D1. Diagnosis is suitably effected by detecting the presence of plexin D1 in the body or a bodily tissue or fluid, whereas treatment is effected by targeting plexin D1 for delivery of therapeutics to the site where treatment is needed. The invention further relates to the use of molecules that bind plexin D1, a nucleic acid encoding plexin D1 or a ligand of plexin D1 for the preparation of a therapeutical composition for the treatment or diagnosis of disorders that involve expression of plexin D1. The disorders comprise disorders in which plexin D1 is expressed on tumor cells, tumor blood vessels or activated macrophages.Type: ApplicationFiled: July 14, 2016Publication date: October 27, 2016Applicant: Modiquest B.V.Inventors: Wilhelmus Petrus Johannes Leenders, Ilse Roodink, Jozef Maria Hendrik Raats
-
Patent number: 9422358Abstract: The present invention relates to plexin D1 for use as a targetable protein in the treatment or diagnosis of disorders that involve expression of plexin D1. Diagnosis is suitably effected by detecting the presence of plexin D1 in the body or a bodily tissue or fluid, whereas treatment is effected by targeting plexin D1 for delivery of therapeutics to the site where treatment is needed. The invention further relates to the use of molecules that bind plexin D1, a nucleic acid encoding plexine D1 or a ligand of plexin D1 for the preparation of a therapeutical composition for the treatment or diagnosis of disorders that involve expression of plexin D1. The disorders comprise disorders in which plexin D1 is expressed on tumor cells, tumor blood vessels or activated macrophages.Type: GrantFiled: July 3, 2012Date of Patent: August 23, 2016Assignee: Modiquest B.V.Inventors: Wilhelmus Petrus Johannes Leenders, Ilse Roodink, Jozef Maria Hendrik Raats
-
Publication number: 20150307603Abstract: This invention is in the field of treating or preventing inflammation in humans and animals and relates to pharmaceutical compositions and methods for treating or preventing various inflammatory conditions. In particular, the invention relates to compositions and methods for treating or preventing inflammatory conditions such as citrulline-related inflammatory diseases. The invention provides specific binding molecules directed against citrulline-containing epitopes for use in the therapy and prevention of inflammatory conditions.Type: ApplicationFiled: June 18, 2015Publication date: October 29, 2015Inventors: Jozef Maria Hendrik Raats, Renato Gerardus Silvano Chirivi
-
Patent number: 9109019Abstract: This invention is in the field of treating or preventing inflammation in humans and animals and relates to pharmaceutical compositions and methods for treating or preventing various inflammatory conditions. In particular, the invention relates to compositions and methods for treating or preventing inflammatory conditions such as citrulline-related inflammatory diseases. The invention provides specific binding molecules directed against citrulline-containing epitopes for use in the therapy and prevention of inflammatory conditions.Type: GrantFiled: December 10, 2010Date of Patent: August 18, 2015Assignee: Modiquest B.V.Inventors: Jozef Maria Hendrik Raats, Renato Gerardus Silvano Chirivi
-
Patent number: RE46990Abstract: This invention is in the field of treating or preventing inflammation in humans and animals and relates to pharmaceutical compositions and methods for treating or preventing various inflammatory conditions. In particular, the invention relates to compositions and methods for treating or preventing inflammatory conditions such as citrulline-related inflammatory diseases. The invention provides specific binding molecules directed against citrulline-containing epitopes for use in the therapy and prevention of inflammatory conditions.Type: GrantFiled: March 3, 2017Date of Patent: August 14, 2018Assignee: MODIQUEST B.V.Inventors: Jozef Maria Hendrik Raats, Renato Gerardus Silvano Chirivi